Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Disease- and treatment-related elevation of the neurodegenerative marker tau in children with hematological malignancies
Autore:
Van Gool, SW; Van Kerschaver, E; Brock, P; Pottel, H; Hulstaert, F; Vanmechelen, E; Uyttebroeck, A; Van De Voorde, A; Vanderstichele, H;
Indirizzi:
Catholic Univ Louvain, Dept Pediat, B-3000 Louvain, Belgium Catholic Univ Louvain Louvain Belgium B-3000 at, B-3000 Louvain, Belgium Innogenet NV, Ghent, Belgium Innogenet NV Ghent BelgiumInnogenet NV, Ghent, Belgium
Titolo Testata:
LEUKEMIA
fascicolo: 12, volume: 14, anno: 2000,
pagine: 2076 - 2084
SICI:
0887-6924(200012)14:12<2076:DATEOT>2.0.ZU;2-P
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACUTE LYMPHOBLASTIC-LEUKEMIA; CENTRAL NERVOUS-SYSTEM; NEURON-SPECIFIC ENOLASE; NO PREVIOUS HISTORY; CEREBROSPINAL-FLUID; PROTEIN CONCENTRATIONS; NEUROLOGICAL DISORDER; ALZHEIMERS-DISEASE; CUSHINGS-SYNDROME; S-100 PROTEIN;
Keywords:
leukemia; tau; neurotoxicity; CSF;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
36
Recensione:
Indirizzi per estratti:
Indirizzo: Van Gool, SW Univ Hosp Gasthuisberg, Expt Immunol Lab, Herestr 49, B-3000 Louvain, Belgium Univ Hosp Gasthuisberg Herestr 49 Louvain Belgium B-3000 ium
Citazione:
S.W. Van Gool et al., "Disease- and treatment-related elevation of the neurodegenerative marker tau in children with hematological malignancies", LEUKEMIA, 14(12), 2000, pp. 2076-2084

Abstract

Children acquire neuropsychologic dysfunctions after chemotherapy for hematologic malignancy. In this study, putative changes in levels of CSF-tau (amarker of neural dysintegrity) in leukemic children prior to and during chemotherapy were studied. Cerebrospinal fluid (CSF) samples were obtained before and during treatment from patients with B cell non-Hodgkin's lymphoma (NHL, n = 10), non-B cell acute lymphoblastic leukemia/NHL (non-B-ALL, n = 48), acute myeloid leukemia (AML, n = 9), other malignant diseases (n = 9),and six control children. A sandwich-type ELISA (INNOTEST hTAU-AS) was used for measuring CSF-tau. Sixteen out of 50 patients with hematological malignancies, including the patients with proven leukemic CNS invasion, alreadyshowed high CSF-tau levels at baseline (>300 pg/ml). The pre-induction treatment for non-B-ALL, consisting of only corticosteroids and methotrexate (MTX), resulted in a significant increase of tau at day 8 ton average to 535pg/ml). Larger increases as compared to baseline levels of CSF-tau were observed in patients treated far B-NHL with systemic vincristine, corticosteroids and cyclophosphamide, and intrathecal MTX (mean 776 pg/ml at day 8). in two AML patients with CNS invasion, CSF-tau increased during chemotherapyup to 1500 and 948 pg/ml, respectively. In one non-B-ALL patient with MTX-induced clinical neurotoxicity, CSF-tau was above the detection limit of 2000 pg/ml. Almost one-third of the patients with hematological malignancies had elevated CSF-tau levels at diagnosis. Transient high levels of CSF-tau,reaching levels observed in other neurodegenerative disorders, were observed during induction chemotherapy for non-B-ALL, B-NHL and CNS+ AML. The clinical implications of both observations will be the subject of further study.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/04/20 alle ore 23:04:49